RT10/10 × 10mg/COA ×4
WGT / Weight Management
Retatrutide (10mg) – RT10
$544.50
per box of 10 vials, 10mg per vial
Box of 10 vials
- Code
- RT10
- Box
- 10 vials
- Per vial
- 10mg
- Form
- Lyophilised powder
- Reports held
- Purity, Sterility, Heavy metals, Endotoxin
- Availability
- In stock
Supplied strictly for laboratory research. Not for human or veterinary consumption, and not for diagnostic or therapeutic use. Handling is the purchaser's responsibility.
Laboratory reports
Reports on file for this batch
About the compound
Retatrutide (10mg) — Research Peptide
Retatrutide (LY3437943) is a synthetic, acylated peptide developed by Eli Lilly and currently in Phase 3 clinical investigation. It is the first triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously to enter large-scale clinical trials, distinguishing it from dual agonists (tirzepatide) and single agonists (semaglutide) currently in clinical use.
Triple Receptor Mechanism
GLP-1R agonism: Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally via hypothalamic pathways to reduce energy intake. This is the shared mechanism with semaglutide and tirzepatide.
GIPR agonism: Potentiates insulin secretion and modulates adipose tissue metabolism. Shared with tirzepatide, hypothesised to contribute to improved tolerability and adipose-specific effects.
GCGR agonism: The distinguishing mechanism. Glucagon receptor activation increases hepatic glucose output and stimulates thermogenesis and lipolysis. When combined with GLP-1R agonism, glycaemic effects of glucagon are buffered while thermogenic and hepatic effects are preserved — a potentially unique metabolic research profile.
Published Phase 2 Data
Phase 2 results published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated dose-dependent body weight reductions of up to ~24% from baseline at 48 weeks in the highest dose cohort, along with reductions in liver fat fraction (MRI-PDFF), triglycerides, and blood pressure. The adverse event profile was consistent with the GLP-1 class.
Product Specifications
- Peptide: Retatrutide (LY3437943)
- Dose: 10mg per vial
- Format: Lyophilised powder, bulk box of 10 vials
- Purity: ≥98% Janoshik HPLC verified
- Testing: Full COA — purity, sterility, endotoxin, heavy metals
- Storage: -20°C. Stable 24 months lyophilised.
For laboratory research use only. Not approved for human therapeutic use in Australia or any other jurisdiction. All products comply with Australian research peptide regulations.
Same area
